Celldex Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

• Celldex Therapeutics Inc CLDX.OQ reported a quarterly adjusted loss of 71 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -83 cents. The mean expectation of twelve analysts for the quarter was for a loss of 73 cents per share. Wall Street expected results to range from -87 cents to -65 cents per share.

• Revenue fell 71.6% to $1.18 million from a year ago; analysts expected $1.12 million.

• Celldex Therapeutics Inc's reported EPS for the quarter was a loss of 71 cents​.

• The company reported a quarterly loss of $47.09 million.

• Celldex Therapeutics Inc shares had fallen by 18.4% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 0.1% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Celldex Therapeutics Inc is $67.50

This summary was machine generated from LSEG data February 27 at 09:47 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)